1. Home
  2. DAL vs INSM Comparison

DAL vs INSM Comparison

Compare DAL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Delta Air Lines Inc.

DAL

Delta Air Lines Inc.

HOLD

Current Price

$70.03

Market Cap

38.2B

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$156.87

Market Cap

33.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAL
INSM
Founded
1924
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.2B
33.5B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
DAL
INSM
Price
$70.03
$156.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
18
24
Target Price
$79.06
$192.27
AVG Volume (30 Days)
8.3M
2.7M
Earning Date
01-13-2026
02-19-2026
Dividend Yield
1.09%
N/A
EPS Growth
43.72
N/A
EPS
7.66
N/A
Revenue
$63,364,000,000.00
$447,022,000.00
Revenue This Year
N/A
$53.83
Revenue Next Year
$5.64
$138.44
P/E Ratio
$9.02
N/A
Revenue Growth
2.79
30.34
52 Week Low
$34.74
$60.40
52 Week High
$73.16
$212.75

Technical Indicators

Market Signals
Indicator
DAL
INSM
Relative Strength Index (RSI) 56.17 39.65
Support Level $64.47 $150.80
Resistance Level $68.30 $165.47
Average True Range (ATR) 2.15 6.33
MACD -0.12 0.26
Stochastic Oscillator 81.12 40.48

Price Performance

Historical Comparison
DAL
INSM

About DAL Delta Air Lines Inc.

Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: